Robert Yeh News Today

Patients with stable angina but a high burden of symptoms benefit from percutaneous intervention (PCI), shows a new analysis of data that caught international attention.

Typical angina predicted PCI's efficacy in ORBITA-2

Interventionalists say it’s now time to make a dent in the complication rate, whether by strict protocols or smaller devices.

Boston Scientific (NYSE:BSX) reported positive investigational device exemption (IDE) trial data for its Agent drug-coated balloon (DCB).

(UPDATED) In patients not taking antianginal meds, PCI clearly alleviated some—but not all—symptoms. What does that mean in practice?

A drug-coated balloon beat conventional balloon angioplasty in treating high-risk patients with in-stent restenosis for outcomes of target lesion restenosis or failure, the AGENT IDE study has shown.

(UPDATED) The results may pave the way for the first coronary DCB available to US physicians. “It’s exciting,” B. Hadley Wilson says.

Agent device avoids additional layer of stenting in patients with recurrent blockages

Bringing Taiwan to the World and the World to Taiwan

Once resurrected, is radiofrequency renal denervation heading back to limbo?